Hematologic Oncology | Specialty

Dr. Cho on Promising Combinations in Multiple Myeloma

March 20th 2019

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses promising combinations in multiple myeloma.

Dr. Holstein on BiTEs in Multiple Myeloma

March 19th 2019

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska Medical Center, discusses the emergence of bispecific T-cell engagers (BiTEs) in multiple myeloma.

Quizartinib Data Move FLT3 Inhibition Forward in AML Paradigm

March 19th 2019

FLT3 inhibition continues to be explored as a therapeutic option for patients with FLT3-mutant acute myeloid leukemia, with quizartinib at the forefront following intriguing results of the phase III QuANTUM-R trial.

Novel Agents Ease Chemotherapy Burden in ALL, But Treating Older Patients Remains a Challenge

March 19th 2019

Immune-based approaches have revolutionized the treatment of acute lymphoblastic lymphoma, especially for patients unable to tolerate multiagent chemotherapy. Now, investigators are looking forward to seeing these agents move into frontline settings, perhaps leading to chemotherapy-free approaches.

Dr. Berdeja Discusses Anticipated Research in Multiple Myeloma

March 19th 2019

Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses anticipated research in the field of multiple myeloma.

Dr. Usmani on Management of Early Relapse in Multiple Myeloma

March 13th 2019

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses the management of early relapse in multiple myeloma.

Dr. Kiladjian on the RUXOPeg Trial in Myelofibrosis

March 12th 2019

Jean-Jacques Kiladjian, MD, PhD, professor of clinical pharmacology, Paris Diderot University, consultant hematologist, head, Clinical Investigation Center, Saint Louis Hospital, Paris, France, discusses the RUXOPeg trial in myelofibrosis.

Stone Highlights Emerging Treatment Options for Older Patients With AML

March 8th 2019

Richard M. Stone, MD, discusses the therapeutic landscape for elderly patients with acute myeloid leukemia.

Therapeutic Breakthroughs in AML Lead to Improvements in OS Outcomes

March 7th 2019

Naval G. Daver, MD, stresses the importance of minimal residual disease testing, and highlights where research in the field is heading in order to achieve a higher cure rate in acute myeloid leukemia.

AML Landscape Explodes With New Agents, But Requires Molecular Monitoring

March 7th 2019

Eytan M. Stein, MD, sheds light on the current treatment landscape of AML, underscores the importance of molecular monitoring, and highlights where the field is headed.

BCL-2 Emerges as an Attractive Target in Solid and Hematologic Cancers

March 6th 2019

Based on the crucial role of BCL-2 family proteins in apoptosis regulation, targeting these proteins using BCL-2 inhibitors offers a potentially new therapeutic option for patients with various types of hematologic malignancies and, more recently, patients with solid tumors.

Dr. Cortes on Exploring the Use of Quizartinib in AML

March 5th 2019

Jorge E. Cortes, MD, deputy chair of the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the data from the QuANTUM-R trial presented at the 2018 ASH Annual Meeting in relapsed/refractory acute myeloid leukemia (AML).

EU Panel Backs Extended Pembrolizumab Dosing Schedule for Single-Agent Indications

March 5th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a new extended dosing schedule for pembrolizumab for all of the PD-1 inhibitor’s monotherapy indications in the European Union.

Using BTK Inhibitors in Community Practice

March 4th 2019

BTK Combination Strategies for B-Cell Malignancies

March 4th 2019

BTK Inhibitors in Chronic Lymphocytic Leukemia

March 4th 2019

New and Emerging BTK Inhibitors in Mantle Cell Lymphoma

March 4th 2019

First-Generation BTK Inhibition in Mantle Cell Lymphoma

March 4th 2019

BTK Inhibitors in Waldenstrom Macroglobulinemia

March 4th 2019

Resistance to BTK Inhibitors in B-Cell Malignancies

March 4th 2019